Peter Young

Senior Venture Partner

Peter joined Pappas Capital in 2012, serving initially as an Executive-in-Residence and then as a Senior Venture Partner until his passing in February 2025.

Peter was an experienced life science industry executive and led the firm’s initiatives in translational medicine. He was the Program Manager for the Wake Forest Technology Development Program, and provided business development and due diligence support to the firm's venture funds and portfolio companies.

Peter had over 40 years of experience in the pharmaceutical and biotechnology industry, spanning all areas of the business from sales representative to country-level general manager and CEO, for companies ranging from multinationals like Abbott and Glaxo to start-up biotechnology companies. As Vice President and Therapy Area Head at Glaxo Wellcome in the mid-1990s, he led the global introduction of combination HIV therapy that revolutionized HIV treatment and quintupled Glaxo’s global HIV portfolio sales, while keying industry leadership on global treatment access. Peter then served as CEO of two private start-up enterprises, a viral vector vaccine company that raised over $80 million in NIH HIV and biodefense vaccine grants, and a specialty pharmaceutical company he led to an exit via a strategic transaction.

Peter served as an observer for Ribometrix, Sorriso Pharmaceuticals and Veralox Therapeutics, on the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research, and on the advisory board for New York State’s Empire Discovery Institute. He was also a member of the Long Island Bioscience Hub External Review Board, an Executive-in-Residence at Cold Spring Harbor Laboratory, an Executive-in-Residence at the Stony Brook University Center for Biotechnology, and a Mentor-in-Residence at Rutgers University. Peter previously served as a member of the BIO board, was past Chairman of the North Carolina Biosciences Organization (NCBIO), and was a director of Memory Pharmaceuticals from 2004 until its sale to Roche in 2009. Over his career he lived and worked in the US, Greece, the Middle East, Puerto Rico, New Zealand and London.

Education:

Indiana University (BA, History)
IU Kelley School of Business (MBA)